EICHORPublic-registry site landscape for NCT07753369, “A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)”, a Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) study sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07753369 (registry record) |
| Study title | A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
| Official title | A Randomized, Open-Label, Multicenter, Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Condition(s) | Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
| Phase | PHASE3 |
| Listed sites | 2 |
| Intervention(s) | TQB3909 Tablets, Bendamustine injection、 Rituximab injection 、Lenalidomide Capsules |
| Site countries | China |
At Henan Province — one of the facilities listed on this trial — 3 other studies are actively recruiting Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) patients at the same facility (public registry, as of August 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Patient-friendly overview of this study: eichor.com/study/NCT07753369.
Eichor generates a preliminary site-risk snapshot for NCT07753369 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
